Inflammation is recognized as a crucial contribution to diabetic nephropathy (DN). CXCL8 binds to its CXC chemokine receptors (CXCR1 and CXCR2) for recruiting neutrophil infiltration and initiates tissue inflammation. Therefore, we explored the effect of CXCR1 and CXCR2 inhibition on DN. This was achieved by CXCL8 K11R/G31P (G31P), an antagonist of CXCL8 that has exhibited therapeutic efficacy in inflammatory diseases and malignancies. In this study, we found that renal leukocyte accumulation and rapid increases of CXCL8 occurred in high-fat diet/streptozocininduced diabetic mice. G31P effectively reduced urine volume, urine albumin/creatinine ratio, blood urea nitrogen, and creatinine clearance rate in mice with diabetes. In addition, renal histopathologic changes including mesangial expansion, glomerulosclerosis, and extracellular matrix deposition were partially moderated in G31P-treated diabetic mice. Furthermore, G31P attenuated renal inflammation and renal fibrosis of diabetic mice by inhibiting proinflammatory and profibrotic elements. G31P also inhibited high glucose-induced inflammatory and fibrotic factor upregulation in human renal mesangial cells. At the molecular level, G31P inhibited activation of CXCR1/2 downstream signaling JAK2/STAT3 and ERK1/2 pathways in in vitro and in vivo experiments. Our results suggest blockade of CXCR1/2 by G31P could confer renoprotective effects that offer potential therapeutic opportunities in DN. (Endocrinology 158: 1671(Endocrinology 158: -1684(Endocrinology 158: , 2017 
D
iabetic nephropathy (DN), a critical diabetic microvascular complication, is the leading cause of endstage renal disease (1) . Prevention of the occurrence and development of DN demands immediate attention because of the high level of mortality and risk for cardiovascular disease (2) . Although our understanding of the disease pathogenesis is expanding, novel therapeutic approaches to control DN are still insufficient (3) . Accumulated evidence suggests that the inflammatory process might exacerbate kidney injury in diabetes, characterized by a massive increase in various inflammatory cells and cytokines (4) (5) (6) .Cytokines such as interleukin-1b (IL-1b), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a) are considered the main regulators of inflammation and are reported to play pivotal roles in the pathogenesis of DN (4) . Inflammatory cells such as macrophages are key mediators of renal damage in DN, and an abnormal, activated status of blood neutrophils has also been reported in patients with DN (5, 7) . Furthermore, the neutrophil/lymphocyte ratio may be a reliable predictor of diabetic renal function because it has been significantly associated with DN (8, 9) .
CXCL8 is a prototypical CXC chemokine relevant to the recruitment and activation of neutrophils via activation of multiple intracellular signaling pathways through two cell-surface G protein-coupled receptors (CXCR1 and CXCR2). Among them, CXCL8 principally binds to CXCR1 with high affinity, whereas CXCL8 and other CXC chemokines bind with CXCR2 (10) . CXCL8 is involved in the pathologic processes of fibrosis, angiogenesis, arteriosclerosis, infection, and tumor growth (11) (12) (13) (14) (15) . Urinary and serum levels of CXCL8 were elevated in patients with DN (16, 17) . However, the mechanism by which CXCL8 affects DN is not well understood.
It has been recognized that fibrosis caused by extracellular matrix (ECM) accumulation has contributed to the progression of DN (18) . Obviously, imbalances between degradation and reorganization of ECM components could accelerate the progression of fibrosis in DN, and fibrosis is closely associated with inflammation in many diseases, including DN (19, 20) . In addition, CXC chemokines involved in the upregulation of ECM synthesis have a reported role in diabetic renal injury (21, 22) .
Because chemokine networks have been involved in progressive renal disorders, the potential antagonists are attractive as a therapeutic option for renal injury. For example, CC chemokine receptor 2 antagonists may reduce renal inflammation and fibrosis mainly via reductions in macrophage infiltration (23, 24) . Accordingly, we have developed a CXCL8 analogue, CXCL8 K11R/G31P (G31P), that replaces Arg and Pro of human CXCL8 with Lys11 and Gly31, respectively (25) . Previous studies have shown that G31P has higher binding affinity than CXCL8 for its receptors (CXCR1 and CXCR2) and that G31P has a high tendency for anti-inflammatory, antitumor, and antifibrosis effects in multiple diseases through selective inhibition of the bioactivity of CXCL8 (26) (27) (28) (29) . In this study, we demonstrated the effects of G31P on kidney tissue damage in diabetic mice and high glucose (HG)-induced human renal mesangial cells (HRMCs). We hypothesized that inhibition of CXCR1 and CXCR2 pathways by G31P would have anti-inflammatory or antifibrotic effects, making G31P an innovative therapeutic strategy for DN.
Materials and Methods
Information regarding related antibodies and reagents is presented in the Appendix Table and in Supplemental Table 1 , respectively.
Cell culture
HRMCs (ATCC) were cultured in Dulbecco's modified Eagle medium (Gibco) (including 5.5 mM of glucose) containing 10% fetal calf serum (Gibco) and penicillin-streptomycin. The six to 15 passage HRMCs were divided into four groups as follows: (1) normal glucose group, cells were cultured in Dulbecco's modified Eagle medium; (2) mannitol control group, cells were cultured in normal medium with an additional 24.4 mM of mannitol supplement, which was served as osmolarity control; (3) HG group, cells were cultured in medium supplemented with an additional 24.5 mM of glucose; and (4) G31P-treated group (HG + G31P group), cells were treated with 100 ng/mL of G31P before HG stimulation.
Animals
All animal experiments were approved by the ethical committee for animal experiments at Dalian Medical University (Dalian, China) and followed the guidelines of the Care and Use of Laboratory Animals, which was revised by the National Institutes of Health. Six-week-old male C57BL/6 mice were purchased and housed at the SPF animal center of Dalian Medical University. A combination of high-fat diet (HFD) and streptozocin (STZ) treatment was used to simulate diabetes and obesity-related kidney disease, as referred to in previous experiments (30) (31) (32) . Initially, 48 mice were randomly divided into two groups. One of the groups (24 mice) was fed with an HFD for 8 weeks to induce insulin resistance and was then given a single injection of STZ [50 mg/kg, intraperitoneally (IP)]. The other group of 24 mice was fed with normal rodent chow and was then injected with an equivalent volume of sodium citrate buffer (IP). Blood glucose levels of the mice were measured using a blood glucose monitor (Roche) after every 3 days. Mice were considered to have diabetic onset with a fasting blood glucose level .16 mmol/L on two consecutive tests. After confirmation of diabetes onset, the diabetic mice were again randomly divided into two groups. One was given a subcutaneous injection of G31P at 0.5 mg/kg on alternate days, and the other group was given an equivalent saline solution. Meanwhile, the remaining 24 mice fed with normal rodent chow were also divided into two groups and treated the same as the diabetic mice. The dosage of G31P has been described in previous studies (27, 28) . Body weight and blood glucose level were strictly measured twice a week during the 12 weeks of treatment.
Biochemical analysis
An IP glucose tolerance test was performed in all groups of mice after G31P treatment. Five random mice in each group were tested with IP injection of 2 g dextrose per kilogram of body weight after an 8-hour fasting period, and then blood samples were collected through the tail vein at different time points. To determine urine volume, different groups of mice were caged in a metabolic cage, and 24-hour urine samples were collected after treatment three times. Serum creatinine, urine creatinine, and blood urea nitrogen levels were analyzed with the corresponding kits (Nanjing Jiancheng Bioengineering Institute), and urine albumin concentrations were determined by enzyme-linked immunosorbent assay (Bethyl Laboratroies).
Renal pathology
All surgeries were performed under anesthesia, and efforts were made to minimize suffering in the mice. Mice kidneys were taken out to measure their weight and were fixed for at least 48 hours with 4% paraformaldehyde. After dehydration, the tissue was embedded in paraffin, sliced into 4-mm-thick sections, and then underwent histological staining, periodic acid-Schiff (PAS) staining, Sirius red staining, and Masson trichrome staining (Masson) (Sirius red kit; Beijing Baiaolaibo Biotechnology Co., Ltd.; PAS and Masson kits; Nanjing Jiancheng Bioengineering Institute). Four mice in each group were randomly chosen, and at least five different fields of each slice were randomly selected for specific staining. Photographs of hematoxylin and eosin (H&E), PAS, and Masson stains were taken using an inverted microscope (Leica), and Sirius red images were taken with a polarization microscope (Leica). The standard for H&E staining is shown in Supplemental Table 2 .The glomerulosclerosis index was calculated according to the PAS-positive area in the glomerulus. Briefly, the evaluation of glomerulosclerosis was divided into five grades: grade 0, little change; grade 1, 1% to 25% (the sclerotic lesions occupied the glomerulus area); grade 2, 26% to 50%; grade 3, 51% to 75%; and grade 4, 76% to 100%. Renal extracellular fibrosis was analyzed using Masson and Sirius red staining. Each field of renal images was calculated using the positive-collagen area of Masson or Sirius red stain and the corresponding renal interstitial area using Image-Pro Plus 6.0 software (Microsoft Media Cybernetics, Bethesda, MD). Finally, the collagen proliferation area/renal interstitial area ratio was used to statistically analyze the ECM in each field of the renal slices.
Immunohistochemistry
Immunohistochemistry (IHC) was performed as described in our previous studies (27, 28) . Biomarkers including transforming growth factor-b (TGF-b; 1:50), phosphorylated nuclear factor kB (NF-kB; 1:50), vascular endothelial growth factor (VEGF; 1:50), podocin (1:100), and nephrin (1:50) were evaluated by IHC. In brief, four mice from each group were randomly taken, and at least five different fields of each slice were randomly selected for observation under an inverted microscope (Leica, Germany). All IHC staining images were observed using the same photo conditions, the same exposure time, and the same optical density value correction. Each image was used to determine the positive-stained area and to calculate the value of integral optical density using Image-Pro Plus 6.0 software. The mean density (each image in different groups of renal tissue) 5 the integral optical density/the positive-stained area value.
Ultrastructure of kidney evaluation
To evaluate the ultrastructure of glomerular basement membrane (GBM) and the podocytic process, kidney tissue was fixed in 3% glutaraldehyde, postfixed with 1% osmium tetroxide, imbued in uranyl acetate, and finally embedded in epoxy resin. The specimens were observed and photographed under a transmission electron microscope (JEM-1200EX II; JEOL, Tokyo, Japan). Electron micrographs were randomly taken from five glomeruli per kidney, with the kidneys randomly taken from three mice in each group. To determine GBM thickness, images were obtained from 10 randomly selected points at the side of the GBM, and then the sum of GBM thicknesses from the points was divided by 10.The value obtained was the average thickness of basement membrane in each image, and the mean value of all obtained data was represented as the average thickness of GBM in each group.
Enzyme-linked immunosorbent assay
The expression of serum CXCL8 in different groups of mice was assessed using an enzyme-linked immunosorbent assay kit (Senbeijia Nanjing Biotechnology Co. Ltd.). The samples were prepared and tested as instructed by the manufacturer.
Cell counting kit-8 assay
Cell viability was determined according to the instructions of cell counting kit-8 (Dojindo). In brief, HRMCs were plated in 96-well plates with different concentrations of G31P. After 24-hour treatment with G31P, medium containing 10 mL of cell counting kit-8 solution was added for 2 hours. Cell viability was determined by absorbance of each well at 450 nm.
Real-time polymerase chain reaction
Total RNA from renal tissue was isolated by a trizol reagent and prepared for complementary DNA synthesis. The SYBR Green PCR Master Mix kit (TaKaRa) was used according to the manufacturer's protocol, and the samples were carried out using a real-time polymerase chain reaction (PCR) system (Life Technologies). A specific primers list is provided in Supplemental Table 3 . Relative expression was determined by using glyceraldehyde 3-phosphate dehydrogenase as a housekeeping reference gene, and the data were presented from three independent experiments. The dissolve and amplification curves of the experiments are shown in Supplemental Fig. 1 .
Western blotting
Renal tissue was homogenized in lysis buffer with protease and phosphatase inhibitors, using the same protocol described in our previous studies (27, 28) . Blots were incubated with primary antibody diluent as follows: CTGF (1:1000), TGF-b (1:2000), ERK1/2 (1:20,000), p-ERK1/2 (1:1000), JAK2 (1:2000), p-JAK2 (1:500), STAT3 (1:5000), and p-STAT3 (1:500). Secondary antibody was used for 1 hour at room temperature. Protein bands were detected using enhanced chemiluminescence reagent, and glyceraldehyde 3-phosphate dehydrogenase (1:5000) was used as an internal reference. The quantitative analysis and photographs of protein bands were performed using a ChemiDoc MP Imaging System (Bio-Rad).
Statistical analysis
Data were expressed as mean 6standard error of the mean. Variance among multiple groups was analyzed using SPSS 19.0 statistical analysis software with the one-way analysis of variance method. A P value ,0.05 was considered statistically significant.
Results

Blockade of CXCR1 and CXCR2 by G31P conferred renoprotection in DN
Compared with control mice, diabetic mice developed remarkable renal hypertrophy, which is shown in Fig. 1(a) and was assessed as a kidney weight/body weight ratio as well (Table 1 ). Diabetic mice with or without G31P injection maintained higher levels of fasting blood glucose and random blood glucose than nondiabetic mice (P , 0.01) ( Table 1 ). Blood glucose levels of diabetic mice were not affected by treatment with G31P (P . 0.05) ( Table 1) . G31P treatment conferred a marked reduction in water intake compared with the untreated diabetic group (P , 0.01) ( Table 1) . Similarly, the alteration of blood urea nitrogen and creatinine clearance rate was markedly improved in G31P-treated diabetic group (P , 0.01) ( Table 1) . Initially, diabetic mice were more obese than control mice because of the HFD, but diabetic mice with or without G31P treatment gradually dropped weight with disease severity. However, there were no significant differences in body weight between G31P-treated and G31P-untreated diabetic groups (P . 0.05) [ Fig. 1(d)] . Meanwhile, the IP glucose tolerance test exhibited obvious abnormal glucose tolerance in diabetic mice, and G31P had little effect on the regulation of blood glucose levels in this group (P . 0.05) [ Fig. 1(e) ]. Diabetic mice had a 9.61-fold increase in 24-hour urinary volume and a 4.66-fold increase in urine albumin/creatinine ratio, whereas treatment with G31P reduced 24-hour urinary volume and urine albumin/creatinine ratio by 28.4% and 38.4%, respectively (P , 0.05) [ Fig. 1(f) and 1(g) ]. Finally, we calculated the mortality rates of mice in the different groups and found that G31P treatment reduced the mortality of diabetic mice (P , 0.01) (Supplemental Fig. 2 ).
G31P improved glomerular structural abnormalities and reduced renal collagen deposition
The phenomenon of glomerular hypertrophy and nodular glomerulosclerosis was displayed in diabetic mice by H&E, but it was attenuated by G31P treatment; meanwhile, nondiabetic mice treated with G31P had few glomerular and tubular morphological changes (P , 0.01) [ Fig. 1(a) and 1(b) ]. Almost normal foot process structures with mild thickening of the GBM were seen in nondiabetic mice with or without G31P treatment. GBM thickness, along with foot process effacement of podocytes, was observed in diabetic mice, but it was widely improved by G31P treatment (P , 0.01) [ Fig. 1(a) and 1(c)]. Mesangial expansion of the kidneys was observed after staining with PAS in all groups; we also examined the effect of G31P on collagen deposition in diabetic kidneys by using Masson and Sirius red staining [ Fig. 2(a) ]. Results showed that G31P treatment resulted in a lower glomerulosclerosis index level than in the untreated diabetic group (P , 0.01) [ Fig. 2(b) ]. G31P treatment significantly attenuated the collagenous fiber deposition in diabetic kidneys (P , 0.01) [ Fig. 2(c) and 2(d) ]. The expression of nephrin and podocin was also significantly decreased in diabetic mice in the immunostaining assays, but G31P treatment partially reversed their expression (P , 0.01) [ Fig. 3(a-c) ]. In particular, G31P ameliorated nephrin and podocin messenger RNA (mRNA) expression downregulation compared with that of untreated diabetic mice (P , 0.05) [ Fig. 3(d) and 3(e) ].
G31P treatment improved fibrosis in DN
Our results showed that the kidneys of diabetic mice had higher TGF-b mRNA and protein levels, which significantly decreased after G31P treatment (P , 0.05) [ Fig. 4(a-d) ]. In addition, G31P treatment reduced expression of connective tissue growth factor (CTGF) and fibronectin in diabetic mice (P , 0.05) [ Fig. 4(d-f) ]. The mRNA levels of ECM degradation-related proteins such as matrix metalloprotein-2 (MMP-2) and matrix metalloprotein-9 (MMP-9) were significantly decreased in the kidneys of STZ-induced diabetic mice, levels that were partially reversed by G31P treatment (P , 0.05) [Fig. 4(g) and 4(h) ].
G31P treatment reduced VEGF and inflammation-related factor expression in DN
VEGF, a cytokine that plays a major role in diabetic glomerular hyperpermeability, displayed elevated A total of 44 mice were divided into four groups: control mice (n = 12), control mice with G31P injection (n = 12), diabetic mice (n = 10), and diabetic mice with G31P injection (n = 10). Water intake, food intake, and blood glucose level were strictly measured twice a week during the experiment. Creatinine and BUN levels in different groups were analyzed with the corresponding kits. Finally, the kidneys were taken out to measure weight. Ccr = U 3 V/P (U, urine creatinine; V, urine volume; P, plasma creatinine). Values are expressed as mean 6standard error of the mean.
Abbreviations: BUN, blood urea nitrogen; BW, body weight; Ccr, creatinine clearance rate; FBG, fasting blood glucose; KW, kidney weight; NS, normal saline; RBG, random blood glucose. a P , 0.01 vs control.
expression in renal tissues of diabetic mice with IHC staining. However, the expression level of VEGF substantially decreased in diabetic mice treated with G31P compared with untreated diabetic mice (P , 0.01) [ Fig. 5 (a) and 5(b)]. NF-kB phosphorylation was also significantly increased in diabetic mice but was largely decreased after G31P treatment (P , 0.01) [ Fig. 5 (a) and 5(c)]. Levels of IL-1b, IL-6, TNF-a, and CXCL8 were markedly increased in the kidneys of diabetic mice compared with those of control mice, and G31P treatment significantly reduced their production (P , 0.01) [ Fig. 5(d-g) ].
G31P reduced macrophage infiltration in diabetic mice kidneys F4/80 was increased in diabetic kidneys compared with the kidneys of control mice, although the increased expression of renal F4/80 was significantly reduced by G31P treatment (P , 0.01) [ Fig. 6(a) ]. Furthermore, there was a substantial increase in CD68 expression in diabetic kidneys; however, the increased CD68 expression was mostly reduced by G31P treatment in real-time PCR results (P , 0.01) [ Fig. 6(b) ].
G31P weakened activation of ERK1/2 and JAK2/STAT3 pathways via binding to CXCR1 and CXCR2
Before G31P treatment, the expression of CXCR1 and CXCR2 was significantly higher in diabetic mice than in control mice; however, it was significantly decreased after G31P treatment as examined by realtime PCR assays (P , 0.01) [ Fig. 6(c) and 6(d) ]. In addition, serum CXCL8 levels in diabetic mice were reduced by G31P treatment (P , 0.05) [ Fig. 6(e) ]. In downstream pathways of CXCR1 and CXCR2, the upregulation of renal phosphorylated JAK2, STAT3, and ERK1/2 in diabetic mice was significantly reduced by G31P treatment [ Fig. 6(f) ].
G31P inhibited HG-induced mesangial cell proinflammatory and profibrosis factor synthesis HG induction caused an increasing expression of TNF-a, TGF-b, and CTGF in mesangial cells compared with expression in the mannitol group; however, G31P decreased their mRNA expression after treatment (P , 0.05) [ Fig. 7(a-c) ]. In addition, 30 mmol/L of glucose caused a transient increase of CXCL8, which attained peak value at 6 hours of HG stimulation (P , 0.01) [ (Fig. 7(d) ]. Cell cytotoxicity with G31P was quantified with the cell counting kit-8 assay, which showed that a moderate dosage of G31P (between 0 and 100 ng/mL) caused no significant cytotoxicity to mesangial cells (P . 0.05) 
Discussion
Abundant evidence, ranging from basic experiments to clinical data, has shown that most chemokines and their receptors were cardinal participators in the progression of DN (21, 23, 24, (33) (34) (35) . However, CXCR4 demonstrated a potential renoprotective role in rats with diabetes (36) . However, our study has demonstrated that elevated CXCL8 level is a critical factor in the progression of renal neutrophil accumulation, which leads to renal injury in diabetic mice. The CXCL8 antagonist G31P, which has high efficacy in inflammatory and fibrotic diseases, was used in STZ-induced diabetic mice. As a result, we found renal dysfunction was attenuated in the G31P treatment group. G31P treatment is largely considered an inhibitor of inflammation. We also considered that G31P could reduce damage to renal cells, especially mesangial cells, directly caused by CXCL8. However, it appeared that G31P had little effect on metabolic factors involved in glucose level and body weight in HFD-/STZinduced mice. The specific cell surface glycoprotein F4/80 is the maker of macrophages, and F4/80-positive macrophages are abundant in the tubulointerstitium. However, F4/80-positive macrophages are also observed in glomeruli in the diabetic condition (37) . CD68 is a member of the lysosomal-associated membrane protein family and is regarded as a macrophage/monocyte marker (38) . Through observation of the markers F4/80 and CD68, G31P treatment strikingly reduced abundant macrophage infiltration in the diabetic kidneys. Secreted CXCL8 mediates events at multiple stages in leukocyte influx into the glomerulus or interstitial space and in the process of leukocyte-endothelium interaction and renal inflammation. In turn, the infiltrating activated leukocytes aggravate the inflammation state, which may increase CXCL8. Our results provide evidence that G31P may influence one of the inflammatory loops between inflammatory cells and chemokines in DN. Previous studies proved that IL-1b promoted mesangial cell proliferation and ECM synthesis (39) . IL-6 and TNF-a levels have been associated with type 1 diabetes, type 2 diabetes, and DN (40, 41) . NF-kB is an upstream regulator of inflammation, which is thought to control activation of numerous genes that are involved in inflammatory processes. Once NF-kB is substantially activated, dramatically increased inflammatory cells and cytokines exacerbate tissue injury (42) . NF-kB was partially activated when CXCL8 was bound to its receptors in HFD/STZ-induced diabetic mice, but G31P inhibited NF-kB activation through competitive binding to CXCR1 and CXCR2. Thus, G31P inhibition of an upsurge in levels of IL-1b, IL-6, and TNF-a expression is associated with its intervention in NF-kB activation. It is now recognized that G31P could drastically diminish inflammation by disturbance of CXCL8 causing an inflamed state.
VEGF is involved in glomerular hyperpermeability, and CXCL8 stimulated VEGF expression (43, 44) . In our results, G31P treatment reduced VEGF expression mainly by its deactivation of CXCL8 functions and the improved high-filtration state of the diabetic kidneys.
Altered expression of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, affected the breakdown and turnover of ECM (19) . Amazingly, administering G31P improved kidney fibrosis, as confirmed by the reduction in ECM. This result was thought to be associated with improvement in MMP-2 and MMP-9 expression through inhibition of CXCL8 functions. Overexpression of TGF-b could accelerate cell proliferation, migration, and ECM deposition in renal injury, and plasma CTGF is a risk marker of diabetic renal and vascular diseases. Meanwhile, the expression of TGF-b was also largely elevated in the inflammation environment, and the expression of CTGF was strongly induced by TGF-b (45) (46) (47) . The reason for reduced ECM deposition in HFD/STZ-induced diabetic mice was also thought to be related to the inhibition of TGF-b and CTGF expression by G31P.
Podocytes play a key role in maintenance of the dynamic barrier of glomerular filtration. Nephrin and podocin expressed by podocytes are crucial for maintaining the integrity of the filtration barrier (48) . The urine nephrin/podocin ratio combined with proteinuria may be worth testing for clinical diagnosis of DN (49) . Treatment through the blockade of CXCR1 and CXCR2 helped protect nephrin and podocin expression, which was possibly dependent on G31P inhibition of fibrosis and inflammation. Both primitive inflammation and fibrosis may accelerate glomerular hyperpermeability and increased urine output. Meanwhile, renal cells play an important role in maintaining glomerular filtration function. G31P treatment could significantly improve glomerular hyperpermeability in diabetic mice. This effect of G31P is largely attributed to its inhibition of inflammation and fibrosis and reduced damage of the renal cells in DN. In conclusion, G31P could offer renoprotective effects from diabetic injury by antagonism of CXCL8.
CXC chemokines bind to their receptors and activate JAK2/STAT3 and ERK1/2 pathways, and these pathways are closely implicated in the pathogenesis of progressive DN (50) (51) (52) (53) (54) . G31P treatment decreased the phosphorylation of ERK1/2, JAK2, and STAT3 in diabetic mice and in HG-treated mesangial cells because it reduced the activation of CXCR1-and CXCR2-mediated downstream JAK2/STAT3 and ERK1/2 pathways.
In conclusion, G31P alleviated inflammation and fibrosis in diabetic kidneys via inhibition of CXCR1-and CXCR2-mediated JAK2/STAT3 and ERK1/2 signaling pathways in in vitro and in vivo experiments. This study successfully demonstrated protection of the diabetic kidney with the blockade of CXCR1 and CXCR2. Several potential problems remain, mainly related to unforeseen immune modulation by the G31P antagonist; however, our results showed that chemokine receptor antagonists, especially G31P, appear to have great potential as therapeutic tools in the treatment of DN. Disclosure Summary: The authors have nothing to disclose.
